Lupin gets USFDA approval for bacterial infection drug

The approval is to market a generic equivalent of bactrim oral suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries.

65
USFDA
Picture: Pixabay

Lupin has received the United States Food and Drug Administration (USFDA) approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL.

The approval is to market a generic equivalent of bactrim oral suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries.

Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).

According to the IQVIA MAT September 2020 data, Sulfamethoxazole and Trimethoprim Oral Suspension USP had estimated annual sales of approximately US $19 million in the US.


Also read | India: Pharma export shoots up, ‘China plus one’ policy helps


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

Click here to open form

LEAVE A REPLY

Please enter your comment!
Please enter your name here